CSF1R is an inclusion criterion in 2 clinical trials for acute lymphoblastic leukemia, of which 2 are open and 0 are closed. Of the trials that contain CSF1R status and acute lymphoblastic leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 3 (1 open) [4].

CSF1R is an inclusion criterion in 2 clinical trials for malignant solid tumor, of which 2 are open and 0 are closed. Of the trials that contain CSF1R status and malignant solid tumor as inclusion criteria, 2 are phase 2 (2 open) [4].

CSF1R is an inclusion criterion in 1 clinical trial for adenocarcinoma of the gastroesophageal junction, of which 1 is open and 0 are closed. Of the trial that contains CSF1R status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 1 is phase 2 (1 open) [4].

CSF1R is an inclusion criterion in 1 clinical trial for B-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains CSF1R status and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [4].

CSF1R is an inclusion criterion in 1 clinical trial for bile duct carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CSF1R status and bile duct carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

CSF1R is an inclusion criterion in 1 clinical trial for bladder carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CSF1R status and bladder carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

CSF1R is an inclusion criterion in 1 clinical trial for breast carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CSF1R status and breast carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

CSF1R is an inclusion criterion in 1 clinical trial for bronchogenic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CSF1R status and bronchogenic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

CSF1R is an inclusion criterion in 1 clinical trial for cervical carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CSF1R status and cervical carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

CSF1R is an inclusion criterion in 1 clinical trial for colorectal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CSF1R status and colorectal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

CSF1R is an inclusion criterion in 1 clinical trial for esophageal squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CSF1R status and esophageal squamous cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

CSF1R is an inclusion criterion in 1 clinical trial for gallbladder carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CSF1R status and gallbladder carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

CSF1R is an inclusion criterion in 1 clinical trial for gastric adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains CSF1R status and gastric adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

CSF1R is an inclusion criterion in 1 clinical trial for head and neck carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CSF1R status and head and neck carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

CSF1R is an inclusion criterion in 1 clinical trial for lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CSF1R status and lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

CSF1R is an inclusion criterion in 1 clinical trial for malignant uterine neoplasm, of which 1 is open and 0 are closed. Of the trial that contains CSF1R status and malignant uterine neoplasm as inclusion criteria, 1 is phase 2 (1 open) [4].

CSF1R is an inclusion criterion in 1 clinical trial for melanoma, of which 1 is open and 0 are closed. Of the trial that contains CSF1R status and melanoma as inclusion criteria, 1 is phase 2 (1 open) [4].

CSF1R is an inclusion criterion in 1 clinical trial for mixed phenotype acute leukemia, of which 1 is open and 0 are closed. Of the trial that contains CSF1R status and mixed phenotype acute leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

CSF1R is an inclusion criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains CSF1R status and multiple myeloma as inclusion criteria, 1 is phase 2 (1 open) [4].

CSF1R is an inclusion criterion in 1 clinical trial for non-small cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CSF1R status and non-small cell lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

CSF1R is an inclusion criterion in 1 clinical trial for ovarian carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CSF1R status and ovarian carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

CSF1R is an inclusion criterion in 1 clinical trial for pancreatic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CSF1R status and pancreatic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

CSF1R is an inclusion criterion in 1 clinical trial for soft tissue sarcoma, of which 1 is open and 0 are closed. Of the trial that contains CSF1R status and soft tissue sarcoma as inclusion criteria, 1 is phase 2 (1 open) [4].